| Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis G DeMaagd, A Philip Pharmacy and therapeutics 40 (8), 504, 2015 | 801 | 2015 |
| Management of urinary incontinence GA DeMaagd, TC Davenport Pharmacy and Therapeutics 37 (6), 345, 2012 | 142 | 2012 |
| The new pregnancy and lactation labeling rule S Pernia, G DeMaagd Pharmacy and therapeutics 41 (11), 713, 2016 | 137 | 2016 |
| Pharmacy practice, research, education, and advocacy for older adults American College of Pharmacy SA Linnebur, MB O'Connell, AM Wessell, AD McCord, DH Kennedy, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 25 (10 …, 2005 | 54 | 2005 |
| Part 2: introduction to the pharmacotherapy of Parkinson’s disease, with a focus on the use of dopaminergic agents G DeMaagd, A Philip Pharmacy and Therapeutics 40 (9), 590, 2015 | 43 | 2015 |
| Parkinson’s disease and its management: Part 3: Nondopaminergic and nonpharmacological treatment options G DeMaagd, A Philip Pharmacy and Therapeutics 40 (10), 668, 2015 | 36 | 2015 |
| High-risk drugs in the elderly population: Nurses, who are at the front lines of health care in all areas of practice, should be aware of drugs that may cause serious problems … G Demaagd Geriatric Nursing 16 (5), 198-207, 1995 | 33 | 1995 |
| The pharmacological management of migraine, part 1: overview and abortive therapy G DeMaagd Pharmacy and Therapeutics 33 (7), 404, 2008 | 32 | 2008 |
| Parkinson’s disease and its management: part 4: treatment of motor complications G DeMaagd, A Philip Pharmacy and therapeutics 40 (11), 747, 2015 | 30 | 2015 |
| The pharmacological management of migraine, part 2: preventative therapy G Demaagd Pharmacy and Therapeutics 33 (8), 480, 2008 | 27 | 2008 |
| Cenobamate: a new adjunctive agent for drug-resistant focal onset epilepsy CT Buckley, OR Waters, G DeMaagd Annals of Pharmacotherapy 55 (3), 318-329, 2021 | 22 | 2021 |
| An overview of overactive bladder and its pharmacological management with a focus on anticholinergic drugs G DeMaagd, JD Geibig P AND T 31 (8), 462, 2006 | 17 | 2006 |
| Parkinson’s disease and its management: Part 5: treatment of nonmotor complications G DeMaagd, A Philip Pharmacy and Therapeutics 40 (12), 838, 2015 | 11 | 2015 |
| ACCP Task Force SA Linnebur, MB O’Connell, AM Wessell, AD McCord, DH Kennedy, ... Pharmacy practice, research, education, and advocacy for older adults …, 2005 | 7 | 2005 |
| The initial examination of the efficacy of low-dose promethazine for the treatment of nausea and vomiting in the hospitalized elderly GH McClintock, RM LaReau, K Watcharotone, G DeMaagd Geriatric Nursing 31 (2), 115-122, 2010 | 5 | 2010 |
| A Review of the Pharmacologic Causes of Delirium in the Elderly GA DeMaagd CONSULTANT PHARMACIST 10, 461-461, 1995 | 4 | 1995 |
| Pharmacists’ Expanding role in immunization practices G DeMaagd, A Pugh US Pharm 48 (10), 34-38, 2023 | 2 | 2023 |
| Migraine headache: The pharmacist and the role of OTC medications G DeMaagd Pharmacy Times 73 (3), 106, 2007 | 2 | 2007 |
| Parkinson Disease and Antiparkinsonian Drugs AE Philip, G DeMaagd, MF Khan Medicinal Chemistry of Drugs Affecting the Nervous System 2, 321-76, 2020 | 1 | 2020 |
| The pharmacotherapy of lipid disorders G DeMaagd PHARMACY TIMES 65, 79-90, 1999 | 1 | 1999 |
